Claims for Patent: 10,420,748

Summary for Patent: 10,420,748

Title:	Methods of treatment associated with the granulocyte colony-stimulating factor receptor
Abstract:	Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.
Inventor(s):	Marschke; Keith B. (La Jolla, CA), Zhi; Lin (La Jolla, CA)
Assignee:	LIGAND PHARMACEUTICALS INCORPORATED (San Diego, CA)
Application Number:	15/908,504
Patent Claims:	1. A method for treating a cancer selected from the group consisting of a leukemia, non-small cell lung cancer, colon cancer, CNS cancer, skin cancer, ovarian cancer, renal cancer, prostate cancer, breast cancer, and myeloma, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula (I), (II), Ill, or (IV) in combination with an additional therapeutic agent selected from the group consisting of a chemotherapeutic agent, bone marrow transplant, and radiation therapy, wherein the compound of Formula (I), (II), Ill, or (IV) has the structure: ##STR00067## a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from hydrogen, OR.sup.6, NO.sub.2, CN, NR.sup.6R.sup.7, CO.sub.2R.sup.6, C(.dbd.O)NR.sup.6R.sup.7, SO.sub.3R.sup.6, SO.sub.2NR.sup.6R.sup.8, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.2-C.sub.6 alkenyl, an optionally substituted C.sub.2-C.sub.6 alkynyl, an optionally substituted C.sub.1-C.sub.6 heteroalkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkenyl, an optionally substituted C.sub.2-C.sub.6 heterocyclyl, an optionally substituted arylalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.2 and R.sup.3 are independently selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.2-C.sub.6 alkenyl, an optionally substituted C.sub.2-C.sub.6 alkynyl, an optionally substituted C.sub.1-C.sub.6 heteroalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkenyl, an optionally substituted C.sub.1-C.sub.6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.4 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.2-C.sub.6 alkenyl, an optionally substituted C.sub.2-C.sub.6 alkynyl, an optionally substituted C.sub.1-C.sub.6 heteroalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkenyl, an optionally substituted C.sub.1-C.sub.6 heterocycle, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, an optionally substituted arylalkynyl, and an optionally substituted heteroarylalkyl; R.sup.5 is selected from hydrogen, halogen, NO.sub.2, CN, CF.sub.3, OR.sup.6, CO.sub.2R.sup.6, C(.dbd.O)NR.sup.6R.sup.7, SO.sub.3R.sup.6, and SO.sub.2NR.sup.6R.sup.8, an optionally substituted aryl, an optionally substituted C.sub.1-C.sub.6 alkyl, and an optionally substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.6 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, a C.sub.1C.sub.6 heteroalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.7 is selected from hydrogen, C(.dbd.O)R.sup.8, C(.dbd.O)NHR.sup.8, an optionally substituted C.sub.1-C.sub.6 alkyl, and an optionally substituted C.sub.1-C.sub.6 heteroalkyl; or --NR.sup.6R.sup.7 is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen; R.sup.8 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, and an optionally substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.9 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.2-C.sub.6 alkenyl, an optionally substituted C.sub.2-C.sub.6 alkynyl, an optionally substituted C.sub.1-C.sub.6 heteroalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkenyl, an optionally substituted C.sub.1-C.sub.6 heterocycle, an optionally substituted heteroaryl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, an optionally substituted arylalkynyl, an optionally substituted heteroarylalkyl, an optionally substituted heteroarylalkenyl, and an optionally substituted heteroarylalkynyl; Q is selected from the group consisting of NR.sup.6, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heteroalkyl, and an optionally substituted non-aromatic heterocycle; L.sup.1 is selected from NH and CHR.sup.2; W is selected from O (oxygen) and NH; X is N (nitrogen) or CR.sup.2; Y is selected from an optionally substituted C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, an optionally substituted C.sub.1-C.sub.6 heteroalkyl, an optionally substituted C.sub.1-C.sub.6 heteroalkenyl, an optionally substituted phenylalkenyl, and an optionally substituted heterocyclealkenyl; Z is O (oxygen) or S (sulfur); and n is 1, 2 or 3. 2. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of an alkylating agent, anthracycline, cytoskeletal disruptor, epothilone, histone deacetylase inhibitor, topoisomerase inhibitor, kinase inhibitor, monoclonal antibody, nucleotide analog, peptide antibiotic, platinum-based agent, retinoid, and vinca alkaloid. 3. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of gemcitabine, cytarabine, cisplatin, methotrexate, 6-mercaptopurine, chlorambucil, cyclophosphamide, fludarabine, pentostatin, cladribine, imatinib, rituximab, interferon-alpha, doxorubicin, vincristine, prednisone, etoposide, bleomycin, and alemtuzumab. 4. The method of claim 1, wherein the pharmaceutical composition and the additional therapeutic agent are administered sequentially. 5. The method of claim 1, wherein the pharmaceutical composition and the additional therapeutic agent are administered concurrently. 6. The method of claim 1, wherein the pharmaceutical composition is administered intravenously. 7. The method of claim 1, wherein the pharmaceutical composition is administered orally. 8. The method of claim 1, wherein the pharmaceutical composition comprises a component selected from the group consisting of a polyethylene glycol, an organic solvent, and a surfactant. 9. The method of claim 1, wherein the leukemia is selected from the group consisting of chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), T-cell prolymphocytic leukemia, large granular lymphocytic leukemia, adult T-cell leukemia, juvenile myelomonocytic leukemia, and hairy cell leukemia. 10. The method of claim 1, wherein the compound has the structure of Formula (Ia): ##STR00068## a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkenyl, an optionally substituted C.sub.2-C.sub.6 heterocyclyl, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.2 and R.sup.3 are independently selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.4 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkenyl, an optionally substituted C.sub.1-C.sub.6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; and Q is selected from an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, and an optionally substituted non-aromatic heterocycle. 11. The method of claim 1, wherein the compound has the structure of Formula (IIa) or (IIb): ##STR00069## a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R.sup.3 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.4 is selected from an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl; and R.sup.9 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heterocyclyl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl. 12. The method of claim 1, wherein the compound has the structure of Formula (IIIa): ##STR00070## a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from hydrogen, OR.sup.6, NR.sup.6R.sup.7, CO.sub.2R.sup.6, C(.dbd.O)NR.sup.6R.sup.7, an optionally substituted C.sub.2-C.sub.6 heterocyclyl, an optionally substituted arylalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.2 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.4 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl; R.sup.5 is selected from hydrogen, halogen, CN, CF.sub.3, OR.sup.6, an optionally substituted aryl, and an optionally substituted C.sub.1-C.sub.6 alkyl; R.sup.6 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; R.sup.7 is selected from hydrogen, C(.dbd.O)R.sup.8, C(.dbd.O)NHR.sup.8, and an optionally substituted C.sub.1-C.sub.6 alkyl; or --NR.sup.6R.sup.7 is an optionally substituted non-aromatic heterocycle linked through a ring nitrogen; R.sup.8 is selected from hydrogen, and an optionally substituted C.sub.1-C.sub.6 alkyl; Q is selected from NR.sup.6, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, and an optionally substituted non-aromatic heterocyclyl; and n is 1, or 2. 13. The method of claim 1, wherein the compound has the structure of Formula (IVa) or (IVb): ##STR00071## a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: R.sup.4 is selected from an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl; R.sup.5 is selected from halogen, CN, CF.sub.3, OR.sup.6, an optionally substituted aryl, and an optionally substituted C.sub.1-C.sub.6 alkyl; R.sup.6 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl; and R.sup.9 is selected from hydrogen, an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.8 cycloalkyl, an optionally substituted C.sub.1-C.sub.6 heterocyclyl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl. 14. The method of claim 1, wherein the compound is selected from the group consisting of: ##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089## ##STR00090## ##STR00091## ##STR00092## a tautomer thereof, or pharmaceutically acceptable salt thereof.

Details for Patent 10,420,748

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-03-15
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2033-03-15
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2033-03-15
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2033-03-15
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2033-03-15